These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37097304)

  • 61. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients.
    Sefrioui D; Mauger F; Leclere L; Beaussire L; Di Fiore F; Deleuze JF; Sarafan-Vasseur N; Tost J
    Clin Chim Acta; 2017 Feb; 465():1-4. PubMed ID: 27940131
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients.
    Tanaka J; Nakagawa T; Harada K; Morizane C; Tanaka H; Shiba S; Ohba A; Hijioka S; Takai E; Yachida S; Kamura Y; Ishida T; Yokoi T; Uematsu C
    Sci Rep; 2023 Feb; 13(1):3039. PubMed ID: 36810451
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
    Gao J; Wu H; Wang L; Zhang H; Duan H; Lu J; Liang Z
    BMJ Open; 2016 Jan; 6(1):e009532. PubMed ID: 26747035
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
    Li Y; Xu Y; Wu X; He C; Liu Q; Wang F
    J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients.
    Park G; Park JK; Son DS; Shin SH; Kim YJ; Jeon HJ; Lee J; Park WY; Lee KH; Park D
    Sci Rep; 2018 Aug; 8(1):11631. PubMed ID: 30072705
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
    Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
    Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cross-Platform Comparison of Four Leading Technologies for Detecting
    Xu T; Kang X; You X; Dai L; Tian D; Yan W; Yang Y; Xiong H; Liang Z; Zhao GQ; Lin S; Chen KN; Xu G
    Theranostics; 2017; 7(6):1437-1446. PubMed ID: 28529628
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Circulating tumor cells in pancreatic cancer : Results of morphological and molecular analyses and comparisons with the primary tumor].
    Timme-Bronsert S; Bronsert P; Werner M; Kulemann B; Höppner J
    Pathologe; 2018 Dec; 39(Suppl 2):311-314. PubMed ID: 30483865
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
    Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
    BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.
    Araki T; Shimizu K; Nakamura K; Nakamura T; Mitani Y; Obayashi K; Fujita Y; Kakegawa S; Miyamae Y; Kaira K; Ishidao T; Lezhava A; Hayashizaki Y; Takeyoshi I; Yamamoto K
    J Mol Diagn; 2010 Jan; 12(1):118-24. PubMed ID: 20007840
    [TBL] [Abstract][Full Text] [Related]  

  • 71. KRAS mutation analysis by droplet digital PCR of duodenal juice from patients with MODY8 and other pancreatic diseases.
    Choi MH; Tjora E; Forthun RB; Engjom T; Ræder H; Hovland R; Molven A
    Pancreatology; 2021 Dec; 21(8):1460-1465. PubMed ID: 34580018
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
    Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
    Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing.
    Herreros-Villanueva M; Bujanda L; Ruiz-Rebollo L; Torremocha R; Ramos R; Martín R; Artigas MC
    Gastroenterol Hepatol; 2022 Oct; 45(8):637-644. PubMed ID: 35092761
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification.
    Pratt ED; Cowan RW; Manning SL; Qiao E; Cameron H; Schradle K; Simeone DM; Zhen DB
    Anal Chem; 2019 Jun; 91(12):7516-7523. PubMed ID: 31072097
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Detection of
    Michaelidou K; Koutoulaki C; Mavridis K; Vorrias E; Papadaki MA; Koutsopoulos AV; Mavroudis D; Agelaki S
    Cells; 2020 Nov; 9(11):. PubMed ID: 33233668
    [No Abstract]   [Full Text] [Related]  

  • 77. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
    Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
    Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
    Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
    Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
    Nitschke C; Markmann B; Walter P; Badbaran A; Tölle M; Kropidlowski J; Belloum Y; Goetz MR; Bardenhagen J; Stern L; Tintelnot J; Schönlein M; Sinn M; van der Leest P; Simon R; Heumann A; Izbicki JR; Pantel K; Wikman H; Uzunoglu FG
    Clin Chem; 2023 Mar; 69(3):295-307. PubMed ID: 36644936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.